口服非甾体抗炎药市场 – 行业趋势和 2030 年预测

口服非甾体抗炎药市场分析及规模

口服非甾体抗炎药 (NSAID) 市场正在增长，原因有多种，包括全球慢性疼痛发病率上升和人口老龄化。美国疾病控制与预防中心估计，2019 年美国约有 20.4% 的成年人患有慢性疼痛。COX-2 选择性和非选择性 NSAID 通常用于治疗慢性疼痛。

Data Bridge Market Research 分析了 2023-2030 年预测期内口服非甾体抗炎药市场的增长率。在上述预测期内，口服非甾体抗炎药市场的预期复合年增长率约为 5.86%。2022 年市场价值为 206.9705 亿美元，到 2030 年将增长至 326410.1 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

口服非甾体抗炎药市场范围和细分

Market Definition

Nonsteroidal anti-inflammatory drugs (NSAIDs) are medicines that are commonly used for pain relief, stress reduction and high temperature control. They are often used to relieve symptoms of periods of pain, sprains and strains, headaches, cold and flu, arthritis and other long-term pain causes. Non-steroidal medications have sedative and anti-inflammatory effects. Inflammation is caused by the COX-1 and COX-2 enzymes which are inhibited by non-steroidal anti-inflammatory medications (NSAIDs). Some common examples of typical non-steroidal anti-inflammatory medications include aspirin, naproxen, ibuprofen, and paracetamol.

Global Oral Nonsteroidal Anti-Inflammatory Drugs Market Dynamics

Drivers

• Rising Cases of Arthritis

The growing incidence of arthritis and other pain-related disorders is expected to support market growth during the forecast period. For instance, according to the CDC, it is projected that around 1 in 4 adults in the U.S., which is approximately 58.5 million people, have been diagnosed with arthritis. And this arthritis is more common in women (23.5%) than men (18.1%). Therefore, the rising prevalence of arthritis is expected to contribute to the growth during the forecast period.

• Higher Adoption of NSAIDS Over Opioids

The most often recommended medications used for the management of mild to severe pain are NSAIDs and opioids. Though, opioid use is linked to severe adverse outcomes. Non-opioid, non-steroidal anti-inflammatory medicines (NSAIDs), that do not include opioids, are the most often prescribed analgesics used for the management of pain. These medications also have antipyretic, analgesic, and anti-inflammatory properties at higher doses.

Opportunities

• Increasing Partnerships and Collaborations

There have been increasing partnerships and collaborations among major market players that are helping create many opportunities in the market growth. For instance, In May-2022, Dr. Reddy’s Laboratories initiated a partnership with South Korea-based HK inno.N Corporation. Through this partnership, Tegoprazan is projected to provide a new option for the treatment of gastric acid-related as well as mobility-impaired diseases such as Gastric and Duodenal ulcers, Erosive/Non-erosive Gastroesophageal Reflux Disease (GERD / NERD), Nonsteroidal anti-inflammatory drug-mediated ulcers, and Helicobacter pylori eradication.

• Increased Product launches

Numerous products are getting launched with respect to the oral nonsteroidal anti-inflammatory drugs market. For instance, In Aug-2021, Dr Reddy's Laboratories introduced over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg in the US market. This tablet is an over-the-counter non-steroidal anti-inflammatory drug (NSAID) that is used as a pain reliever and fever reducer. Thus, it creates opportunity for the market growth.

Restraints/Challenges

• Side Effect of NSAIDS

The market growth is projected to be constrained by adverse reactions to NSAID use, including stomach pain, allergic reactions, stomach ulcers, and dizziness. The most common reason for most emergency hospital admissions is GI bleeding associated with NSAIDs. Furthermore, its side effect is the most typical drug side in the U.S.

• High Cost

The huge expenditure of the treatment methods hamper the market growth. The high cost of different drugs, surgeries and many such processes are hindering market growth.

This oral nonsteroidal anti-inflammatory drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the oral nonsteroidal anti-inflammatory drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In May-2022, Dr. Reddy's Laboratories released Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market. This product is a nonsteroidal anti-inflammatory drug (NSAID) recommended for the short-term management of moderately serious acute pain, that offers analgesia at the opioid stage and used only as continuation treatment after intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.

Global Oral Nonsteroidal Anti-Inflammatory Drugs Market Scope

The oral nonsteroidal anti-inflammatory drugs market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Penecillins
• Cephalosporins
• Tetracyclins
•  Sulfonamides
• Others

Treatment

• Bactericidal
• Bacteriostatic

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

口服非甾体抗炎药市场区域分析/见解

对口服非甾体抗炎药市场进行了分析，并按类型、治疗、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

口服非甾体抗炎药市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于主要药品生产商的参与、高额的研发和医疗保健支出以及高素质的专业人员，北美预计将拥有最高的市场增长。

亚太地区由于健康报销计划、较高的偏头痛发病率和强有力的政策支持而占据市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球口服非甾体抗炎药市场份额分析

口服非甾体抗炎药市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对口服非甾体抗炎药市场的关注有关。

口服非甾体抗炎药市场的主要参与者包括：

• 拜耳公司（德国）
• 辉瑞公司 (美国)
• 利洁时集团有限公司（英国）
• 诺华公司（瑞士）
• 第一三共株式会社（日本）
• Zydus 集团 (印度)
• 鲁冰花（印度）
• 葛兰素史克公司 (英国)
• Glenmark 制药公司（印度）
• Amneal Pharmaceuticals（美国）
• 阿斯利康（英国）

SKU-56360